Page last updated: 2024-08-25

rosiglitazone and Coronary Restenosis

rosiglitazone has been researched along with Coronary Restenosis in 8 studies

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's6 (75.00)29.6817
2010's2 (25.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chen, S; Dai, J; Hua, J; Mao, W; Qiu, Y; Xu, X; Zhou, X; Zhu, M1
Bruskina, O; Byrne, RM; Cagliero, E; Crimins, J; Daher, M; Finn, AV; Gold, HK; Hendricks, M; John, MC; Kastrati, A; Nadelson, J; Oh, JS; Palacios, I; Schömig, A1
Brugaletta, S; García-García, HM; Garg, S; Huang, C; Kolatkar, NS; Kravitz, BG; Miller, DM; Morocutti, G; Nesto, RW; Ratner, RE; Serruys, PW1
Evans, M; Rees, A; Roberts, AW; Thomas, A1
Brizolara, A; Fitzgerald, P; Osman, A; Otero, J; Stouffer, G; Uretsky, BF; Waxman, S1
Ahn, CW; Cha, BS; Choi, D; Choi, SH; Jang, Y; Kim, SK; Ko, YG; Lee, HC; Lim, SK1
Chilton, R; Sulistio, MS; Thukral, N; Zion, A1

Reviews

3 review(s) available for rosiglitazone and Coronary Restenosis

ArticleYear
Different Effects of Thiazolidinediones on In-Stent Restenosis and Target Lesion Revascularization after PCI: A Meta-Analysis of Randomized Controlled Trials.
    Scientific reports, 2017, 10-31, Volume: 7, Issue:1

    Topics: Angioplasty, Balloon, Coronary; Constriction, Pathologic; Coronary Angiography; Coronary Restenosis; Drug-Eluting Stents; Humans; Myocardial Revascularization; Odds Ratio; Percutaneous Coronary Intervention; Pioglitazone; Randomized Controlled Trials as Topic; Risk Factors; Rosiglitazone; Stents; Thiazolidinediones; Treatment Outcome

2017
Peroxisome proliferator-activated receptor-gamma agonists in atherosclerosis: current evidence and future directions.
    Current opinion in lipidology, 2003, Volume: 14, Issue:6

    Topics: Albuminuria; Arteriosclerosis; Blood Pressure; C-Reactive Protein; Carotid Arteries; Coronary Restenosis; Diabetes Mellitus, Type 2; Endothelin-1; Endothelium, Vascular; Humans; Hyperglycemia; Insulin Resistance; Lipoproteins; Matrix Metalloproteinases; Metformin; Muscle, Smooth, Vascular; Pioglitazone; Plasminogen Activator Inhibitor 1; PPAR gamma; Rosiglitazone; Thiazolidinediones

2003
PPARgamma agonists and coronary atherosclerosis.
    Current atherosclerosis reports, 2008, Volume: 10, Issue:2

    Topics: Animals; Coronary Artery Disease; Coronary Restenosis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fatty Acids, Nonesterified; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; PPAR gamma; Randomized Controlled Trials as Topic; Rosiglitazone; Stents; Thiazolidinediones; Triglycerides

2008

Trials

4 trial(s) available for rosiglitazone and Coronary Restenosis

ArticleYear
Predictive factors for in-stent late loss and coronary lesion progression in patients with type 2 diabetes mellitus randomized to rosiglitazone or placebo.
    American heart journal, 2009, Volume: 157, Issue:2

    Topics: Aged; Angioplasty, Balloon, Coronary; Biomarkers; Coronary Angiography; Coronary Restenosis; Coronary Stenosis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Progression; Double-Blind Method; Female; Humans; Male; Middle Aged; Predictive Value of Tests; Prognosis; Rosiglitazone; Stents; Thiazolidinediones; Vasodilator Agents

2009
Evaluation of in-stent restenosis in the APPROACH trial (Assessment on the Prevention of Progression by Rosiglitazone On Atherosclerosis in diabetes patients with Cardiovascular History).
    The international journal of cardiovascular imaging, 2012, Volume: 28, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Coronary Vessels; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Drug-Eluting Stents; Female; Glipizide; Humans; Hyperplasia; Hypoglycemic Agents; Male; Metals; Middle Aged; Neointima; Predictive Value of Tests; Prospective Studies; Prosthesis Design; Rosiglitazone; Stents; Thiazolidinediones; Time Factors; Treatment Outcome; Ultrasonography, Interventional

2012
Effect of rosiglitazone on restenosis after coronary stenting in patients with type 2 diabetes.
    American heart journal, 2004, Volume: 147, Issue:5

    Topics: Administration, Oral; Adult; Aged; Cardiovascular Agents; Coronary Angiography; Coronary Restenosis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Rosiglitazone; Stents; Thiazolidinediones

2004
Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes.
    Diabetes care, 2004, Volume: 27, Issue:11

    Topics: Adult; Aged; Coronary Angiography; Coronary Restenosis; Coronary Stenosis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Rosiglitazone; Stents; Thiazolidinediones; Treatment Outcome; Vasodilator Agents

2004

Other Studies

1 other study(ies) available for rosiglitazone and Coronary Restenosis

ArticleYear
Diabetes drug may also benefit blood vessels.
    Mayo Clinic health letter (English ed.), 2003, Volume: 21, Issue:11

    Topics: Angioplasty, Balloon, Coronary; Coronary Restenosis; Diabetic Angiopathies; Humans; Hypoglycemic Agents; Rosiglitazone; Thiazolidinediones

2003